Who is sponsoring NCT02613728?

NCT02613728 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02613728?

Interventions in NCT02613728: Accelerated Recovery Plan, Early Discharge, Telemedicine, Standard Enhanced Care.

What condition does NCT02613728 study?

NCT02613728 studies Colorectal Cancer.

Is NCT02613728 still recruiting?

NCT02613728 is currently completed. Last updated 15 March 2022.

Last reviewed 2022-03-15 · How we verify

NCT02613728

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI)

Completed NA Last updated 15 March 2022

What this trial tests

NA trial testing Accelerated Recovery Plan in Colorectal Cancer in 32 participants. Completed in 8 March 2022.

Timeline

13 May 2016

Primary endpoint
8 March 2022

8 March 2022

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	32
Start date	13 May 2016
Primary completion	8 March 2022
Estimated completion	8 March 2022
Sites	1 location across United States

Drugs / interventions tested

Accelerated Recovery Plan
Early Discharge
Telemedicine
Standard Enhanced Care

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 18 to 79, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn if RecoverMI care can help to shorten the time that patients are in the hospital after surgery and if it can help them recover sooner. RecoverMI includes the following parts: * Preoperative Education * Early oral intake * Early mobilization * Telemedicine

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Randomized clinical trial of accelerated enhanced recovery after minimally invasive colorectal cancer surgery (RecoverMI trial).
Bednarski BK, Nickerson TP, You YN, Messick CA, et al · · 2019 · cited 54× · PMID 31216065 · DOI 10.1002/bjs.11223
Accelerated enhanced Recovery following Minimally Invasive colorectal cancer surgery (RecoverMI): a study protocol for a novel randomised controlled trial.
Price BA, Bednarski BK, You YN, Manandhar M, et al · · 2017 · cited 8× · PMID 28729319 · DOI 10.1136/bmjopen-2017-015960
Patient reported satisfaction levels with the use of telemedicine for general surgery-A systematic review of randomized control trials.
Blount E, Davey MG, Joyce WP. · · 2023 · cited 3× · PMID 36570642 · DOI 10.1016/j.sipas.2022.100152

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02613728 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 15 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02613728.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing